Jazz Pharmaceuticals plc

NasdaqGS:JAZZ Stock Report

Market Cap: US$7.5b

Jazz Pharmaceuticals Balance Sheet Health

Financial Health criteria checks 1/6

Jazz Pharmaceuticals has a total shareholder equity of $3.7B and total debt of $5.7B, which brings its debt-to-equity ratio to 153%. Its total assets and total liabilities are $11.4B and $7.7B respectively. Jazz Pharmaceuticals's EBIT is $810.7M making its interest coverage ratio 2.8. It has cash and short-term investments of $1.6B.

Key information

153.0%

Debt to equity ratio

US$5.72b

Debt

Interest coverage ratio2.8x
CashUS$1.63b
EquityUS$3.74b
Total liabilitiesUS$7.66b
Total assetsUS$11.39b

Recent financial health updates

Recent updates

Is Jazz Pharmaceuticals (NASDAQ:JAZZ) A Risky Investment?

Feb 18
Is Jazz Pharmaceuticals (NASDAQ:JAZZ) A Risky Investment?

Updated View On Jazz Pharmaceuticals' 2025 Goals

Jan 29

Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Price Is Right But Growth Is Lacking

Dec 26
Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Price Is Right But Growth Is Lacking

Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly

Oct 31
Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly

Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?

Jul 12
Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?

We Think Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Stay On Top Of Its Debt

Apr 12
We Think Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Stay On Top Of Its Debt

Jazz Pharmaceuticals: Monopoly In The Narcolepsy Drug Market

Aug 24

Jazz begins phase 3 trial of cannabis drug Epidiolex for rare epilepsy

Aug 18

Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly

Aug 10
Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly

Jazz Pharmaceuticals: Strong Launch Of Xywav In Idiopathic Hypersomnia

Jun 08

Jazz Pharmaceuticals (NASDAQ:JAZZ) Takes On Some Risk With Its Use Of Debt

May 12
Jazz Pharmaceuticals (NASDAQ:JAZZ) Takes On Some Risk With Its Use Of Debt

Jazz Pharmaceuticals: Imminent Danger With A Worrying History

Feb 04

Financial Position Analysis

Short Term Liabilities: JAZZ's short term assets ($3.4B) exceed its short term liabilities ($1.5B).

Long Term Liabilities: JAZZ's short term assets ($3.4B) do not cover its long term liabilities ($6.1B).


Debt to Equity History and Analysis

Debt Level: JAZZ's net debt to equity ratio (109.3%) is considered high.

Reducing Debt: JAZZ's debt to equity ratio has increased from 57.9% to 153% over the past 5 years.

Debt Coverage: JAZZ's debt is not well covered by operating cash flow (19.1%).

Interest Coverage: JAZZ's interest payments on its debt are not well covered by EBIT (2.8x coverage).


Balance Sheet


Discover healthy companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.